Amgen Inc. $AMGN Shares Bought by Wealthfront Advisers LLC

Wealthfront Advisers LLC lifted its holdings in Amgen Inc. (NASDAQ:AMGN) by 10.1% during the first quarter, HoldingsChannel reports. The institutional investor owned 90,562 shares of the medical research company’s stock after purchasing an additional 8,275 shares during the period. Wealthfront Advisers LLC’s holdings in Amgen were worth $31,864,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Robeco Institutional Asset Management B.V. boosted its holdings in shares of Amgen by 10.0% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after acquiring an additional 43,884 shares during the period. Curtis Advisory Group LLC acquired a new stake in shares of Amgen in the 4th quarter worth about $1,669,000. Adell Harriman & Carpenter Inc. increased its holdings in shares of Amgen by 7.9% in the 4th quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock worth $7,204,000 after acquiring an additional 1,609 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in Amgen in the 4th quarter valued at about $22,441,000. Finally, Robinhood Asset Management LLC bought a new stake in Amgen in the 4th quarter valued at about $17,526,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.85% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. Mizuho lifted their target price on Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a research note on Tuesday, June 16th. Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a research report on Thursday, June 18th. The Goldman Sachs Group set a $389.00 price target on Amgen in a research note on Friday, June 5th. Finally, UBS Group raised their price target on Amgen from $400.00 to $420.00 and gave the company a “buy” rating in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $356.62.

Amgen Stock Performance

AMGN opened at $358.32 on Thursday. The business has a 50 day moving average price of $346.15 and a two-hundred day moving average price of $350.00. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The company has a market capitalization of $193.39 billion, a price-to-earnings ratio of 24.94, a price-to-earnings-growth ratio of 3.59 and a beta of 0.41. Amgen Inc. has a 1-year low of $269.77 and a 1-year high of $391.29.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts predict that Amgen Inc. will post 22.31 EPS for the current fiscal year.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.